Carolin C. Hack | Medicine and Dentistry | Best Scholar Award

Posted on by World Top Scientists

Dr. Carolin C. Hack | Medicine and Dentistry | Best Scholar Award

Deputy clinical director at Erlangen University Hospital Women’s Clinic, Germany

Priv.-Doz. Dr. med. Carolin Christine Hack is an accomplished medical professional and the Deputy Director of the Women’s Clinic at the University Hospital Erlangen. With a specialization in gynecological oncology and integrative medicine, Dr. Hack combines her clinical expertise with a passion for patient-centered care. Her innovative approach to medicine, along with her extensive training and research, positions her as a leading figure in her field.

Profile

Scopus

Education 🎓

Dr. Hack completed her medical degree at Friedrich-Alexander University Erlangen-Nuremberg, where she also pursued her habilitation in “Integrative Medicine in the Treatment of Gynecological Oncology Patients.” Her academic journey included a comprehensive curriculum that laid the groundwork for her clinical and research interests, ultimately leading to a robust foundation in both conventional and integrative medicine.

Experience 💼

With over a decade of experience at the University Hospital Erlangen, Dr. Hack has advanced through various roles, from assistant physician to Deputy Director of the Women’s Clinic. She has managed quality assurance initiatives and specialized in integrative medicine, focusing on the intersection of traditional and complementary therapies in patient care. Her leadership in the clinic has fostered a collaborative environment that emphasizes innovative treatment methodologies.

Research Interests 🔍

Dr. Hack’s research primarily focuses on integrative medicine and complementary therapy methods, with a specific emphasis on mammographic density as a risk factor for breast cancer. Her work seeks to enhance patient outcomes through evidence-based practices that incorporate holistic approaches to treatment.

Awards 🏆

Dr. Hack’s contributions to gynecological oncology have been recognized with multiple awards, including:

  • 2015: Klaus-Dieter-Schulz-Versorgungsforschungspreis
  • 2016: First Science Award from the German Society for Senology
  • 2018: Award from the Foundation for Women and Child Health
  • 2022: Research Award for Complementary Medicine from NATUM e.V.

Publications 📚

Dr. Hack has an extensive publication record, including:

  • The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype
    • Authors: Ziegler, P., Hartkopf, A.D., Wallwiener, M., Schneeweiss, A., Goossens, C.
    • Journal: BMC Cancer
    • Year: 2024
    • Volume: 24(1), Article 1284
  • Tumor-Associated Neutrophils Are a Negative Prognostic Factor in Early Luminal Breast Cancers Lacking Immunosuppressive Macrophage Recruitment
    • Authors: Schmidt, E., Distel, L., Erber, R., Fietkau, R., Schnellhardt, S.
    • Journal: Cancers
    • Year: 2024
    • Volume: 16(18), Article 3160
  • Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole
    • Authors: Fasching, P.A., Hack, C.C., Nabieva, N., Fehm, T.N., Häberle, L.
    • Journal: European Journal of Cancer
    • Year: 2024
    • Volume: 209, Article 114239
  • Correlation of RANK and RANKL with mammographic density in primary breast cancer patients
    • Authors: Wunderle, M., Heindl, F., Behrens, A.S., Fasching, P.A., Emons, J.
    • Journal: Archives of Gynecology and Obstetrics
    • Year: 2024
    • Volume: 310(2), pp. 1223–1233
  • CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – An Overview of Current Programs
    • Authors: Schneeweiss, A., Brucker, S.Y., Huebner, H., Fehm, T.N., Fasching, P.A.
    • Journal: Geburtshilfe und Frauenheilkunde
    • Year: 2024
    • Volume: 84(5), pp. 443–458
  • Initial experience with a next-generation low-field MRI scanner: Potential for breast imaging?
    • Authors: Dietzel, M., Laun, F.B., Heiß, R., Uder, M., Ohlmeyer, S.
    • Journal: European Journal of Radiology
    • Year: 2024
    • Volume: 173, Article 111352
  • Unbiased high-dimensional flow cytometry identified NK and DC immune cell signature in Luminal A-type and triple negative breast cancer
    • Authors: Heger, L., Heidkamp, G.F., Amon, L., Beckmann, M.W., Dudziak, D.
    • Journal: OncoImmunology
    • Year: 2024
    • Volume: 13(1), Article 2296713
  • Predicting mammographic density with linear ultrasound transducers
    • Authors: Behrens, A., Fasching, P.A., Schwenke, E., Beckmann, M.W., Emons, J.
    • Journal: European Journal of Medical Research
    • Year: 2023
    • Volume: 28(1), Article 384
  • Evaluation of automated techniques for extraction of circulating cell-free DNA for implementation in standardized high-throughput workflows
    • Authors: Lehle, S., Emons, J., Hack, C.C., Ruebner, M., Huebner, H.
    • Journal: Scientific Reports
    • Year: 2023
    • Volume: 13(1), Article 373
  • Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study
    • Authors: Hack, C.C., Maass, N., Aktas, B., Hein, A., Fasching, P.A.
    • Journal: Geburtshilfe und Frauenheilkunde
    • Year: 2023
    • Volume: 84(2), pp. 185–195

Conclusion ✨

Priv.-Doz. Dr. med. Carolin Christine Hack is an exemplary candidate for the Best Researcher Award. Her innovative contributions to integrative medicine and gynecological oncology, coupled with her extensive publication record and commitment to patient care, position her as a leader in her field. By addressing areas for improvement, such as interdisciplinary collaboration and public engagement, Dr. Hack can further enhance her impact in research and continue to advance the frontiers of medical knowledge.

Shahab Reaeian | Prevention | Best Researcher Award

Posted on by World Top Scientists

Assoc Prof Dr. Shahab Reaeian | Prevention | Best Researcher Award

Academic member, Kermanshah University of Medical Sciences, Iran

Dr. Shahab Rezaeian is an esteemed epidemiologist from Iran, specializing in public health and epidemiology. With a PhD from Shiraz University of Medical Sciences, he has dedicated his career to understanding the dynamics of diseases and their impact on communities. He is currently a faculty member at Kermanshah University of Medical Sciences, contributing to the field through both research and education. 🩺📚

Publication Profile

Google scholar

Education

Dr. Rezaeian earned his B.S. in Public Health from Iran University of Medical Sciences in 2007, followed by an MSc in Epidemiology from Hamadan University of Medical Sciences in 2012. He completed his PhD in Epidemiology at Shiraz University of Medical Sciences in 2016, focusing his research on the survival trends and blood demand of beta-thalassemia patients. 🎓

Experience

Dr. Rezaeian has extensive experience in epidemiological research, particularly in assessing the risk factors for various health conditions, including congenital hypothyroidism and HIV. His professional journey reflects a commitment to advancing public health through rigorous data analysis and interpretation. 💼

Research Focus

His primary research interests include epidemiological modeling, public health interventions, and the study of congenital conditions. Dr. Rezaeian aims to contribute to effective health policies and practices by analyzing health data and identifying key determinants of health outcomes. 🔬📈

Awards and Honours

Dr. Rezaeian has received several accolades for his contributions to epidemiology and public health, including recognition for his impactful research publications and involvement in various health initiatives. His work continues to inspire future generations of health professionals. 🏆

Publication Top Notes

Dr. Rezaeian has authored numerous significant publications in reputable journals, contributing to the scientific community’s understanding of epidemiology and public health. Some notable works include:

Influenza A (H1N1) in Hamedan Province, Western Iran in 2009: A Case-Control Study (2010, J Res Health Sci) – Cited by 30

Quality of Cohort Studies Reporting Post the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement (2011, Epidemiology and Health) – Cited by 50

The Quality of the Reporting of Randomized Controlled Trials after CONSORT Statement in the Prestigious Journals (2013, Shiraz E Medical Journal) – Cited by 40

Difference in the Incidence of Congenital Hypothyroidism Among World Countries (2013, Ann Saudi Med) – Cited by 20

Social Determinants of Health Associated with Self-Reported HIV Testing Among Women (2013, Iran J Public Health) – Cited by 35

Risk Factors of Congenital Hypothyroidism Using Propensity Score: A Matched Case-Control Study (2013, J Res Health Sci) – Cited by 25

Mario Flores | Computational Biology | Next-Generation Science Trailblazer Award

Posted on by World Top Scientists

Assist Prof Dr. Mario Flores | Computational Biology | Next-Generation Science Trailblazer Award

Biomedical, University of Texas at San Antonio, United States

Profile

Google Scholar

Short Bio

Dr. Mario A. Flores is an Assistant Professor at the University of Texas at San Antonio, specializing in artificial intelligence models for disease phenotype predictions, biomarker identification, and explainable mechanisms. His innovative research integrates various AI techniques to enhance our understanding of disease progression, particularly in oncology.

Education

Dr. Flores holds a Bachelor’s degree in Electronics Engineering from the Metropolitan Autonomous University, a Master’s in Applied Mathematics, and a PhD in Electrical Engineering (Computational Biology) from the University of Texas at San Antonio. He completed his postdoctoral fellowship at the National Center for Biotechnology Information (NCBI), NIH.

Experience

Since 2020, Dr. Flores has served as an Assistant Professor with joint appointments in Electrical and Computer Engineering (ECE) and Biomedical Engineering (BME) at UTSA. His prior roles include NIH Postdoctoral Fellow at NCBI and Research Associate at the Greehey Children’s Cancer Research Institute, showcasing his extensive experience in computational biology and bioinformatics.

Research Interests

Dr. Flores’s research focuses on developing AI tools for disease gene dependence prediction, utilizing spatially resolved transcriptomics, single-cell RNA sequencing, and Electronic Health Records (EHRs) to analyze tumor microenvironments. His work aims to bridge gaps in understanding disease mechanisms and improve patient outcomes through precision medicine.

Awards

Dr. Flores has received numerous awards for his research, including funding from the NIH for projects on neural circuits inhibiting pain, and recognition from the AIM-AHEAD Fellowship program, supporting his efforts to address health disparities in minority populations.

Publications Top Notes

Dr. Flores has authored several impactful publications, including:

New tools for spatial biology transcriptomics & proteomics in immuno-oncology, Immuno-Oncology Insights, 2023.

Deep learning tackles single-cell analysis—a survey of deep learning for scRNA-seq analysis, Brief in Bioinformatics, 2022.

Transformer for Gene Expression Modeling (T-GEM): An Interpretable Deep Learning Model for Gene Expression-Based Phenotype Predictions, Cancers, 2022.